FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Kesponses	5)																	
1. Name and Address of Reporting Person* Niihara Yutaka					2. Issuer Name and Ticker or Trading Symbol Emmaus Life Sciences, Inc. [EMMA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director _X_ 10% Owner						
(Last) (First) (Middle) 21250 HAWTHORNE BLVD., SUITE 800					3. Date of Earliest Transaction (Month/Day/Year) 12/06/2021								X Officer (give title below) Other (specify below) Chairman and CEO						
(Street) TORRANCE, CA 90503				4. If A	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting PersonForm filed by More than One Reporting Person						
(Ch) (Ch) (T)							rities A	cquire	equired, Disposed of, or Beneficially Owned										
(Instr. 3) Date (Month/Day/Year)		Execution iny	A. Deemed 3. Transaction Code (Instr. 8)		on	(A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			6. Ownership Form: Direct (D) or Indirect	Indirect Benefic Owners	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
		Code V Amount (A) or (D) Price			(I) (Instr. 4)			,											
Common value	stock, \$0.	001 par	12/06/202	1				P		1,500	A	\$ 1.49 (1)	11,0	091,706	6		D (2)		
Common stock, \$0.001 par value		12/07/2021					P		1,900	A	\$ 1.55 (3)	11,0	11,093,606		D (2)				
Common stock, \$0.001 par value		12/08/202	/08/2021				P		1,200	A	\$ 1.58 (4)	11,0	11,094,806		D (2)				
Common stock, \$0.001 par value		12/09/2021					P		2,000	A	\$ 1.69 (5)	11,0	11,096,806			D (2)			
Common value	stock, \$0.	001 par											92,7	794			I	By Ho International Hospid Inc. (6	ational ce,
Common stock, \$0.001 par value												63,0	000			I	By So Niihar		
Reminder:	Report on a s	separate line	for each clas	s of secu	rities ber	neficial	ly o	wned dir	ectly	or indirec	tly.								
									C	ontained	in thi	s form	are n	ot requ	tion of inf ired to res OMB cont	pond	unless	SEC 147	74 (9-02)
			T							, Disposed				Owned					
Security or Exercise (Month/Day/Year) any		Deemed cution Da	4. Transaction Code Year) (Instr. 8)		ion	5.	ve es d d	ns, convertible securi Date Exercisable ad Expiration Date Month/Day/Year)		le ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	Deriva Securit Benefi Owned Follow Report	tive Ortices Forcially Delaying Delaying or ction(s)	wnership orm of erivative ecurity: rect (D) Indirect	11. Nature of Indirec Beneficial Ownershij (Instr. 4)		
						Code	V	(A) (I		Date Exercisable		ration	Title I	Amount or Number of Shares					

	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Niihara Yutaka 21250 HAWTHORNE BLVD. SUITE 800 TORRANCE, CA 90503	X	X	Chairman and CEO					

Signatures

Yutaka Niihara, M.D., M.P.H.	12/10/2021
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.40 to \$1.55, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnotes (3), (4) and (5) to this Form 4.
- (2) The shares shown include shares owned jointly with Soomi Niihara, the reporting person's wife.
- (3) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.53 to \$1.56, inclusive.
- (4) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.56 to \$1.65, inclusive.
- (5) The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$1.60 to \$1.78, inclusive.
- (6) Hope International Hospice, Inc, is a California corporation of which Dr. Niihara and his wife are the sole shareholders and directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.